| Literature DB >> 27470506 |
Meredith Hays1, Mary Andrews1, Ramey Wilson1, David Callender2, Patrick G O'Malley1, Kevin Douglas1.
Abstract
OBJECTIVE: The aim of this study was to assess adherence to the Consolidated Standards of Reporting Trials (CONSORT) for Abstracts by five high-impact general medical journals and to assess whether the quality of reporting was homogeneous across these journals.Entities:
Keywords: CONSORT for Abstracts; compliance; guideline*; quality of report*; randomized controlled trials
Mesh:
Year: 2016 PMID: 27470506 PMCID: PMC4985789 DOI: 10.1136/bmjopen-2016-011082
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1MEDLINE search strategy.
Figure 2CONSORT for Abstracts checklist.
Figure 3Flow diagram of the study.
Journal characteristics
| Journal | Impact factor* | Use of CONSORT endorsed | Overall adherence† (%) |
|---|---|---|---|
| 54.42 | Yes‡ | 55 | |
| 16.104 | Yes‡ | 70 | |
| 39.207 | Yes | 78 | |
| 16.378 | Yes | 65 | |
| 35.289 | Yes‡ | 63 |
*As determined by ISI Impact Factor 2014.
†Overall adherence to checklist items per journal based on our study findings.
‡No explicit mention of CONSORT for Abstracts in instructions to authors.
NEJM, The New England Journal of Medicine; Annals IM, the Annals of Internal Medicine; The BMJ, the British Medical Journal; JAMA, the Journal of the American Medical Association.
Adherence by checklist item
| Variable | Observations | Mean | 95% CI |
|---|---|---|---|
| Title | 463 | 0.79 | 0.75 to 0.83 |
| Trial design | 463 | 0.51* | 0.44 to 0.55 |
| Eligibility criteria | 463 | 0.76* | 0.72 to 0.80 |
| Study setting | 463 | 0.58* | 0.54 to 0.63 |
| Intervention | 463 | 0.87 | 0.83 to 0.90 |
| Objective | 463 | 0.96* | 0.93 to 0.97 |
| Primary outcome | 463 | 0.91 | 0.88 to 0.93 |
| Random sequence generation | 463 | 0.19 | 0.15 to 0.22 |
| Allocation concealment | 463 | 0.08 | 0.06 to 0.11 |
| Blinding | 228 | 0.60 | 0.53 to 0.66 |
| Number of randomised per group | 463 | 0.61* | 0.56 to 0.65 |
| Number of analysed per group | 463 | 0.44* | 0.39 to 0.48 |
| Outcome stated | 463 | 0.83 | 0.79 to 0.86 |
| Effect size/precision | 463 | 0.81 | 0.78 to 0.85 |
| Harms or side effects | 463 | 0.50* | 0.45 to 0.54 |
| Interpretation stated | 463 | 0.99 | 0.98 to 1.00 |
| Trial registration | 463 | 0.96 | 0.94 to 0.98 |
| Source of funding | 463 | 0.53* | 0.48 to 0.57 |
| Overall adherence | 8099 | 0.67 | 0.66 to 0.68 |
*χ2 test for homogeneity among journals was statistically significant (p<0.001).
Adherence to checklist items by individual journal
| Variable | |||||
|---|---|---|---|---|---|
| Title (%) | 9* | 95 | 97 | 100 | 98 |
| Trial design | 30* | 70 | 61 | 59 | 39 |
| Eligibility criteria | 57 | 77 | 83 | 84 | 78 |
| Study setting | 18* | 74 | 52 | 85 | 67 |
| Intervention | 78 | 88 | 92 | 88 | 87 |
| Objective | 81 | 100 | 99 | 100 | 99 |
| Primary outcome | 90 | 86 | 95 | 90 | 90 |
| Random sequence generation | 0 | 21 | 62† | 7 | 3 |
| Allocation concealment | 0 | 17 | 22 | 3 | 0 |
| Blinding | 24* | 85 | 80 | 73 | 35* |
| Number of randomised per group | 34* | 53 | 77 | 66 | 69 |
| Number of analysed per group | 32 | 33 | 65 | 43 | 41 |
| Outcome stated | 85 | 73 | 88 | 74 | 93 |
| Effect size/precision | 77 | 85 | 80 | 81 | 85 |
| Harms or side effects | 69† | 38 | 66 | 28 | 43 |
| Interpretation stated | 98 | 100 | 100 | 98 | 100 |
| Trial registration | 97 | 89 | 99 | 95 | 97 |
| Source of funding | 98 | 76 | 94 | 3* | 2* |
| Overall adherence | 55 | 70 | 78 | 65 | 63 |
*Journals lagged the majority by 25% or more (p<0.001) for the category.
†Journals led the majority by 25% or more (p<0.001) for the category.